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The Badrenergic agonist isoproterenol stimulates inositol trisphosphate (IP,) formation and cytosolic Ca*+ ([Ca”]i) mobilization in rat parotid 
a&i via a CAMP-dependent process. Atropine, a muscarinic antagonist, inhibited these isoproterenol responses without affecting isoproterenol- 
induced amylase secretion or peak [Ca”J and IP, responses elicited by a,-adrenergic stimulation with epinephrine. Atropine had no effect on isopro- 
terenol-induced [Ca”]i responses in a cell line which lacked muscarinic receptors and did not alter b-adrenoreceptor ligand binding. These results 
suggest hat the inhibition by atropine results from a post-receptor effect on CAMP-mediated stimulation of phosphatidylinositol4,5 bisphosphate 
(PIP,) hydrolysis. 
Ca2+ mobilization; Cyclic AMP; Parotid; Receptor crosstalk; Atropine 
1. INTRODUCTION 
Siginal transduction is an intricate process whereby 
an extracellular stimulus is translated into a cellular 
response [l-6]. This includes binding of an agonist to its 
receptor, binding and activation of a specific G protein 
to this hormone-receptor complex (i.e. release of 
GaGTP), stimulation of an effector enzyme by the ac- 
tivated G protein, and finally generation of an ap- 
propriate second messenger. Several steps in this pro- 
cess can be independently regulated. For example, the 
binding of an agonist to its receptor can be dissociated 
from receptor-G protein binding [7-l 31. Recent reports 
have shown evidence for interactions between distinct 
components of cellular second messenger systems (e.g. 
CAMP, IP3, protein kinase C, [Ca*‘]i) [4,14-171. For 
example, in different cell types CAMP can inhibit [18] 
or activate [19-211 the IP3 generating system. We have 
provided examples of the latter effect in both rat 
parotid acinar cells [20] and B82 mouse fibroblasts [22]. 
In this report, we show that atropine, acting at 
muscarinic receptors, can specifically inhibit [Ca’+]i 
mobilization induced by isoproterenol, acting at p- 
adrenoreceptors, and by 8 BrcAMP by a mechanism 
likely involving regulation of PIP2 hydrolysis at a com- 
mon post-receptor site. 
2. MATERIALS AND METHODS 
Parotid acinar cells were prepared from male rats by enzymatic 
digestion using procedures and sources for chemicals described 
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previously [20]. For [Ca*+]i measurements, cells were incubated with 
20,~M quin 2-AM (Calbiochem) and fluorescence changes determined 
with an SLM 8000 spectrofluorimeter as reported [20]. At this concen- 
tration of quin 2, there is no significant buffering of [Ca*+]i (i.e. pat- 
tern and magnitude are similar to results with fura 2) and no altera- 
tion in cell fluid secretory capacity (Ca*+-activated Cl- efflux) [23]. 
PIP2 hydrolysis was followed as IP3 formation and was determined 
30 s after agonist stimulation of cells as described [20]. Amylase secre- 
tion was followed for 30 min using a modified Bernfeld assay 
[20,23,24]. The binding of [3H]quinuclidinyl benzilate ([3H]QNB, 33 
Ci/mmol; New England Nuclear) and [‘2sI]iodocyanopindolol 
([‘*‘I]CYP, 22,000 Ci/mmol) to cell membranes was performed as 
previously described [10,25]. B82 cells were maintained in culture as 
previously described [lo]. Data were analyzed for statistical 
significance using a Student’s t-test assuming a normal distribution of 
values. 
3. RESULTS AND DISCUSSION 
Isoproterenol (200 PM) and 8 BrcAMP (2 mM) in- 
crease [Ca*+]i in rat parotid acinar cells (fig.lA,C). 
Atropine (0.1 PM) totally inhibits the [Ca*+]i elevation 
induced by 1OpM carbachol but is without effect on the 
isoproterenol-mediated response. However, when the 
atropine concentration is increased to 10 ,uM, both the 
carbachol and isoproterenol-mediated changes in 
[Ca*+]i are abolished (fig.lB). In addition, 10 PM 
atropine blocks the elevation of [Ca’+]i elicited by 8 
BrcAMP (fig. lD), suggesting that the inhibitory effect 
of atropine is manifested after CAMP formation. Fur- 
thermore, lO/rM atropine does not inhibit either basal 
or isoproterenol-stimulated amylase secretion from 
acinar cells (table l), demonstrating that the muscarinic 
antagonist does not non-specifically block ,&adreno- 
receptor mediated events. 
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Fig.1. Effect of atropine on stimulated [Ca’+]i mobilization in rat 
parotid acinar cells. Data shown are representative quin 2 
fluorescence traces of 3-5 experiments performed. Experiments 
shown in traces C and D were performed in the presence of 5 mM 
EGTA. The following agents were added at the arrows: Atr, lo-’ M 
(0.1 pM atropine), Atr, lo-’ M (1OrM atropine), Carb (10gM car- 
bachol), Iso (200 pM isoproterenol), Epi (10 pM epinephrine), 8 
BrcAMP (2 mM 8 BrcAMP). 
Changes in [Ca2+]i are somewhat distal to receptor 
activation and may be affected by several Ca2+ flux 
processes. Therefore, we examined the effect of 
atropine on PIPz hydrolysis (IP3 formation) induced by 
isoproterenol. The data (table 1) clearly demonstrate 
that 10 /rM atropine inhibits the isoproterenol-induced 
elevation of IP3. This suggests that the atropine inhibi- 
tion of isoproterenol-stimulated [Ca’+]i changes likely 
results secondarily from the inhibition of PIP2 
hydrolysis. The effects of atropine on /3-adrenergic 
responses do not extend to a,-adrenergic events. The 
peak [Ca*+]i change (fig.lB,D) obtained after 
epinephrine (10 ,uM) stimulation (806 jll49 nM, n = S), 
is unaffected by atropine (774+ 144 nM, n = 9). 
Similarly, epinephrine-mediated IP3 generation (table 
1; - 2 fold basal) remains unchanged in the presence of 
atropine. Although epinephrine is a mixed agonist, ac- 
ting on both cy- and @-adrenergic receptors [26] the 
[Ca2+]i mobilization responses induced by 10 ,uM 
epinephrine are primarily cul-adrenergic receptor- 
mediated [27]. The results discussed above support the 
specific nature of the inhibitory effects of atropine on 
isoproterenol and CAMP induced [Ca2+]i mobilization 
and IP3 generation. 
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We next examined the possible effect of atropine on 
isoproterenol-induced [Ca”]i changes in B82 cells, a 
mouse fibroblast cell line which lacks muscarinic recep- 
tors. I382 cells can mobilize [Ca’+]i and increase I& 
levels after &adrenergic stimuli [22]. As shown in fig.2, 
atropine has no effect on isoproterenol-induced [Ca’+]i 
changes in B82 cells. This finding strongly suggests that 
the inhibitory effect of atropine is dependent upon the 
presence of muscarinic receptors. Although we observ- 
ed that 10 FM atropine was without effect on isopro- 
terenol-induced amylase secretion, and thus unlikely to 
interfere with ligand binding to the fl-adrenoreceptor, 
this possibility was directly examined, Atropine (0.1, 1 
and 10 PM) had no significant effect on the specific 
binding of [“‘I]CYP to B82 cell membranes (96 + 8%, 
92 t 9%) and 90 + 8%, respectively, of control, lOO%, 
values). Specific binding of [1251]CYP was -65% of 
total binding in these studies. Similarly, it is conceivable 
that our findings in parotid cells were a result of 
isoproterenol (or 8 BrcAMP) actions on the muscarinic 
receptor. Accordingly, we measured the binding of 
13H]QNB to parotid membranes in the absence or 
presence of either 200 ,uM isoproterenol (k ATP) or 2 
mM 8 BrcAMP. The specific binding of [3H]QNB was 
unaffected by these agents (97.4-99.0% of control, 
lOO%, values), whereas carbachol, at a 20”fold lower 
concentration than isoproterenol, displaced - 35% of 
the specifically bound tH]QNB. Specific binding of 
[3H]QNB was 50-60% of total binding in these studies. 
In addition, since it has been reported that rat parotid 
acinar cell preparations may contain contaminating 
nerve terminals [28], we assessed the possibility that 
200 FM isoproterenol might induce the release of 
acetycholine from these contaminants. This situation 
would mean that the isoproterenol-induced, and 
Table 1 
Effect of atropine on agonist-stimulated IP3 formation and amylase 
secretion in rat parotid acinar cells 
Treatment 
i;: inositol pool) 
Amylase 
(010 release) 
Control (no addition) 
Isoproterenol (200 CM) 
Epinephrine (10 PM) 
Atropine (10 aM) 
Atropine (10 @I) + 
0.111r0.OW (16) 
0.157+0.012 (12)’ 
0.208 + 0.010 ( 3)* 





isoproterenol (200 PM) 
Atropine (10pM) + 
0.093 * 0.017 ( 5) 134 
epinephrine (10 PM) 0.219*0.020 ( 5)’ n.d. 
IP3 and amylase were determined as described in the text. Data for IP3 
formation are the mean + SE for the number of experiments hown 
in parentheses. IP3 levels which are significantly different (P< O.Ol), 
by Student’s t-test, from control values are indicated by an asterisk. 
Amylase data are the average of two separate xperiments and are ex- 
pressed relative to the amount released detected with isoproterenol- 
stimulated samples (i.e., 100 %). In these experiments i oproterenol- 
stimulated amylase release was 45070 in 30 min; n.d. = not determined 







Fig.2. Effect of atropine on ,&adrenoreceptor-induced levations of 
[Ca’+]r in B82 cells. Data shown are representative quin 2 
fluorescence traces of 3 experiments performed. Iso (200 CM 
isoproterenol), Atr (10 PM atropine) and Carb (10 PM carbachol) 
were added at the arrows. 
atropine-inhibited, changes in [Ca*+]; and IP3 were only 
indirectly elicited. However, when parotid acinar cells 
were incubated in the presence of acetylcholine sterase 
(0.1-S U/ml), there was no effect on isoproterenol- 
stimulated [Ca*+]i mobilization events (not shown). 
In aggregate, our data demonstrate that the 
muscarinic antagonist atropine, by a mechanism which 
requires the presence of muscarinic receptors, can in- 
hibit the stimulation of PIP2 hydrolysis induced by the 
,&adrenergic agonist isoproterenol (via CAMP). We 
have previously suggested that CAMP likely acts at a site 
distal to the muscarinic receptor. An important implica- 
tion of our present findings is that atropine, in addition 
to its well-established pharmacological ability to 
displace cholinergic agents from muscarinic receptors, 
can induce post-receptor effects. This is further sup- 
ported by our data which show that atropine does not 
inhibit CAMP mediated IP3 generation, by a 
mechanism which is independent of the muscarinic 
receptor. It is tempting to speculate that the inhibitory 
effect of atropine occurs at the level of receptor-G pro- 
tein interactions. This conclusion is consistent with 
observations made on [3H]QNB binding to cardiac 
membranes in the absence or presence of GTP by 
Burgisser et al. [29]. Their results suggested that the 
QNB-muscarinic receptor binding process involved a G 
protein interaction (i.e. a post-muscarinic receptor 
change brought about by an antagonist). They propos- 
ed a ‘reciprocal binding’ model to describe the effect of 
GTP on [3H]QNB receptor binding, which is also sup- 
ported by data obtained with other systems [30-351. Ac- 
cordingly, we suggest, based on our findings, that there 
is a post-receptor convergence of the mechanisms in- 
volved in the regulation of PIP2 hydrolysis via the 
muscarinic receptor and another intracellular signalling 
system (CAMP-linked). 
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